Therapixel

What Therapixel does

Therapixel is a privately held French software company founded in 2013 in Nice by INRIA researchers Pierre Fillard and Olivier Clatz, focused exclusively on artificial intelligence for medical imaging, specifically breast cancer screening. Its sole commercial product, MammoScreen, is an FDA-cleared (510(k) K192854 for 2D in 2020 and K211541 for 3D Digital Breast Tomosynthesis in 2021) and CE-marked (January 2021) deep learning computer vision application that automatically detects and characterizes suspicious lesions and calcifications on mammograms and assigns a 1–10 MammoScreen Score indicating malignancy probability. The system is trained on a proprietary database of more than 8 million images, supports explainable AI outputs, and compares current exams against prior mammograms to refine predictions; clinical studies published in Radiology: AI demonstrated an AUC improvement from 0.769 to 0.797 and a sensitivity gain of +0.033 (P = .021) when radiologists used the tool.

The company sells MammoScreen through a SaaS subscription model with quote-based, multi-year enterprise licensing, targeting radiology departments, breast imaging centers, healthcare provider networks (IDNs), and organized national screening programs. Distribution combines direct enterprise field sales with channel and OEM partnerships, including deployments via Onsite Women's Health (150+ US sites), Mayo Clinic radiology departments, and a PACA-region study with CRCDC Sud PACA in France. The company employs 51–100 people across offices in Nice (headquarters), Paris, and Chicago, has raised more than €20 million across Series A (€5M, 2019) and Series B (€15M, 2022), and is ISO/IEC 27001 and GDPR compliant.

Name

Therapixel

Legal name

Therapixel SA

Website

https://therapixel.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

51–100 employees

Short description

Therapixel is a French AI software company that develops and sells MammoScreen, an FDA-cleared and CE-marked deep learning SaaS application that assists radiologists in detecting breast cancer on 2D and 3D screening mammograms, serving hospitals, IDNs, and imaging networks.

Ownership category

akta.pro rank

Product category

Medical Imaging AI Software

NAICS

Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Medical Imaging AI (HDAAAEAH)

akta.pro secondary industries

Mammography & Breast Imaging Systems (HLAHABAF), Women’s Imaging & Breast Health Centers (HLAFAJAJ)

Keywords

• Medical imaging AI
• Breast cancer detection
• Mammography analysis software
• Radiology decision support
• AI mammography screening

Headquarters

HQ city

Nice

HQ country

France

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. SaaS Subscription Model: Therapixel operates on a Software-as-a-Service (SaaS) subscription model for its MammoScreen AI software. Healthcare facilities pay licensing fees for access to the AI-powered mammography analysis platform. The company provides customer quotes based on facility needs and usage patterns.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Therapixel develops and sells MammoScreen, an FDA-cleared and CE-marked AI software that assists radiologists in interpreting screening mammograms (both 2D and 3D/Digital Breast Tomosynthesis). The software automatically detects and characterizes suspicious lesions and calcifications, assigns a 1-10 MammoScreen Score representing malignancy probability, and uses prior exam comparisons to improve detection of cancers that would otherwise be diagnosed one to two years later. The product is delivered as a SaaS subscription to hospitals, cancer centers, imaging networks, and organized screening programs.

Product overview

Therapixel offers a single unified product—MammoScreen®—an AI-powered medical imaging software for breast cancer screening. The software assists radiologists in interpreting both 2D mammography and 3D Digital Breast Tomosynthesis (DBT) exams by automatically detecting suspicious lesions and calcifications, scoring each finding on a 1-10 malignancy probability scale. MammoScreen represents the evolved form of the algorithm that won the Digital Mammography DREAM Challenge in 2017 and has since been enhanced with additional model families and prior exam analysis capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

• MammoScreen® FDA-cleared and CE-marked AI-powered decision support software that assists radiologists in interpreting screening mammograms (both 2D and 3D/Digital Breast Tomosynthesis). The software automatically detects and characterizes suspicious lesions and calcifications, assigns a MammoScreen Score™ (1-10 scale) indicating malignancy probability, and leverages prior exam comparisons to detect cancers earlier. Targeted at hospitals, cancer centers, breast imaging practices, healthcare networks, and organized screening programs.

Quantifiable outcome

• Average AUC improved from 0.769 without AI to 0.797 with AI assistance (multi-reader multi-case study published in Radiology: AI)
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature4 records

Partnerships

Five partnerships are on record, tiered core and strategic.

• CureMetrixcoreTechnology or Integration · 9 December 2025Integration partnership combining Therapixel's MammoScreen (breast cancer detection AI) with CureMetrix's cmAngio (FDA-cleared breast arterial calcification detection). The combined platform enables radiologists to screen for both breast cancer and breast arterial calcifications through a unified installation, expanding access to both AI solutions across healthcare providers.
• Onsite Women's HealthcoreStrategic or Co-development Partner · 3 April 2025Strategic partnership to deploy MammoScreen AI across Onsite Women's Health's national network of 150+ locations. The collaboration aims to enhance breast cancer detection and provide radiologists with AI-driven insights. Onsite serves patients across 26 states and has performed over 2 million exams since 2008. Both companies share a mission to improve outcomes for women through earlier cancer detection.
• Solutions ImagingstrategicStrategic or Co-development Partner · 19 October 2022Collaboration for prospective clinical study evaluating AI in second reading of screening mammograms in the PACA region of France. Solutions Imaging provides Gédéon software for dematerialization of mammography images for second reading, working with 8 radiology offices and CRCDC Sud PACA. The study involves 5,000 women and explores combining digital workflow with AI.
• CRCDC Sud PACAstrategicStrategic or Co-development Partner · 19 October 2022Regional cancer screening coordination center partnering in prospective clinical study for AI-assisted second reading. The study is the first French experiment in organized screening evaluating AI in second reading across 8 radiology offices.
• RAD-AID InternationalstrategicStrategic or Co-development Partner · 16 October 2020Collaboration to donate and support AI for making breast cancer screening more accessible in impoverished regions of the world. RAD-AID's partner sites in low and middle-income countries (LMICs) can receive Therapixel software through RAD-AID's educational collaborations. RAD-AID operates programs in 35 countries across Africa, Asia, Latin America and the Caribbean with over 12,000 volunteers.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• DeepHealth (a RadNet company): DeepHealth, acquired by RadNet, develops AI tools for breast and broader radiology including mammography triage and Saige-Dx. With RadNet's imaging center footprint, it competes for AI-driven breast imaging workflows and is a scaled emerging player.
• Lunit: Lunit develops AI for mammography (Lunit INSIGHT MMG) and other cancer imaging, with growing US and European commercial presence. It is an emerging pure-play medical imaging AI vendor competing for similar hospital and screening program customers.
• Densitas: Densitas provides AI-powered breast density assessment and mammography quality analytics. It serves breast imaging centers with software that overlaps MammoScreen's clinical end users and complements some of the same screening workflows.

Broad incumbents

• Hologic: Hologic manufactures the dominant installed base of mammography systems in the US and offers Genius AI as part of its breast health portfolio. As the modality OEM, it competes with and could displace Therapixel at the point of purchase.
• GE HealthCare: GE HealthCare offers a broad radiology AI portfolio including mammography AI partnerships and its Edison platform. It can bundle AI into imaging equipment and enterprise contracts, putting Therapixel in competition with a much larger sales apparatus.
• Siemens Healthineers: Siemens Healthineers offers AI-Rad Companion and integrated mammography AI capabilities across its imaging portfolio. As an OEM and enterprise imaging vendor, it competes for the same hospital AI budget as Therapixel.

Direct peers

• Volpara Health Technologies: Volpara builds AI-driven breast imaging software including density assessment, risk prediction, and mammography reporting. It targets the same radiology and breast center customers as Therapixel with an overlapping product portfolio focused on breast cancer screening workflows.
• ScreenPoint Medical: ScreenPoint Medical offers Transpara, an AI system for breast cancer detection on 2D mammography and Digital Breast Tomosynthesis. It serves radiologists globally and competes head-to-head with MammoScreen on both modalities.
• iCAD Inc. iCAD markets ProFound AI, an FDA-cleared deep-learning mammography decision-support tool used by radiologists for breast cancer detection. It is one of the most direct competitive analogs to MammoScreen in clinical workflow and customer base.
• CureMetrix: CureMetrix markets cmAngio, an FDA-cleared AI for detecting breast arterial calcifications, and is a current integration partner of Therapixel. It addresses the same breast imaging customer base and could be both a partner and a competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/therapixel
• Facebookfacebook.com/therapixel
• LinkedInlinkedin.com/company/therapixel

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds4 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Therapixel